-

Wall Street Ignored OST as $1B Mirage Grew — Levi & Korsinsky, LLP

Wall Street Reassessment: Zero Institutional Coverage Left Retail Investors Defenseless Against OST's Alleged $950M Pump-and-Dump

NEW YORK--(BUSINESS WIRE)--The absence of Wall Street analyst coverage of Ostin Technology Group Co., Ltd. (Nasdaq: OST) left retail investors without any independent professional assessment as the stock surged 1,175% on fabricated demand. Contact Levi & Korsinsky, LLP to find out if you can recover your OST investment losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

OST shares collapsed from $9.40 to $0.55 on June 26, 2025, a loss of $8.85 per share (94.1%), destroying over $950 million in market capitalization. The lead plaintiff deadline is April 17, 2026.

The Coverage Vacuum That Enabled the Alleged Fraud

Unlike stocks covered by institutional research desks, OST operated in a coverage desert. No major brokerage published earnings models, target prices, or independent assessments of the company's $38 million annual revenue or negative 27% profit margins. As the complaint details, institutional ownership remained frozen at 0.1% throughout the Class Period, a signal that professional money managers saw nothing to justify participation.

The absence of sell-side scrutiny meant no analyst challenged the extraordinary disconnect between OST's deteriorating fundamentals and its exploding stock price. No research note questioned how a company requiring multiple reverse stock splits and carrying a debt-to-equity ratio of 9.5 could sustain a $1 billion market capitalization.

Why the Absence of Analyst Scrutiny Matters for Investors

- No sell-side analyst published a price target, rating, or research report on OST during the Class Period

- Institutional ownership at 0.1% meant zero professional portfolio managers validated the price surge

- OST's market capitalization jumped 4,445% (from $22 million to over $1 billion) without a single institutional buy recommendation

- The company announced no earnings surprises, contract wins, or technological breakthroughs that would typically attract Wall Street attention

- Retail investors on platforms including Hargreaves Lansdown, Trading 212, and AJ Bell became the dominant buyers, relying on fraudulent WhatsApp promotions instead of professional research

Retail Investors Left Without a Counterweight

The lawsuit chronicles how fraudulent promoters filled the void that analyst coverage would have occupied. Deepfake videos impersonating Goldman Sachs strategists, fabricated acquisition rumors supported by fake 20-page reports, and WhatsApp groups dispensing daily buy instructions replaced the independent research that typically serves as a check on unsupported price movements. Victims spanned the United States, United Kingdom, Germany, Israel, Canada, and Italy.

"When analyst expectations are built on incomplete or misleading company disclosures, the resulting corrections can cause significant investor harm. In this case, the complete absence of professional coverage created a vacuum that was allegedly exploited by those orchestrating the scheme." -- Joseph E. Levi, Esq.

Speak with an attorney about recovering your losses from the OST fraud or call (212) 363-7500.

LEAD PLAINTIFF DEADLINE: April 17, 2026

Levi & Korsinsky, LLP, Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered for investors.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NASDAQ:OST

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)

NEW YORK--(BUSINESS WIRE)--Roughly seven out of every ten dollars invested in EyePoint Pharmaceuticals (NASDAQ: EYPT) common stock was wiped out when shares fell nearly 67% following the Company's disclosure that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO wet AMD trial. If you held EYPT shares through that decline, you are encouraged to have your EYPT losses reviewed now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at...

GLOB Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Globant (GLOB)

NEW YORK--(BUSINESS WIRE)--Shareholders of Globant (NYSE: GLOB) absorbed a sharp decline in the shares after the Company's Q2 2026 earnings release, which reported revenue of approximately $614.4 million and a reduced full-year 2026 revenue forecast. Investors who lost money on GLOB are encouraged to request a review of your GLOB losses now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The reported quarter came in below street...

PRIM Deadline Alert: Levi & Korsinsky Reminds Primoris Services Corporation (PRIM) Investors of Securities Class Action Deadline on September 21, 2026

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP notifies investors in Primoris Services Corporation (NYSE: PRIM) that a class action has been filed on behalf of shareholders who purchased securities between August 5, 2025 and June 22, 2026. See if you could be eligible to recover or call (212) 363-7500.PRIM fell $23.39 per share, or 21.6%, from $108.34 to $84.95 on June 23, 2026. The lead plaintiff deadline is September 21, 2026.Primoris Timeline Disclosure Events Alleged in the ComplaintTh...
Back to Newsroom